InvaGen Pharmaceuticals Plans to Open New Islip, NY, Facility & Create 400 Jobs
01/27/2012
Located in Long Island, NY, InvaGen is a fast-growing generic pharmaceutical company. About 330 workers are employed at its drug product development and commercial operations at three different Hauppauge, NY, facilities.
Construction activity (dependent upon obtaining building permits) could begin as early as February, and will transform one building into a manufacturing, research lab and packaging operation. The firm will invest $20 million in the purchase and renovation part of the project, and $19 million more later in new equipment and research.
Plans call for the revamped facility to be fully operational in five years. The firm anticipates hiring 150 employees within the first two years and paying them an average wage of around $50,000 (according to documents it filed with the Islip Industrial Development Agency).
InvaGen will receive almost $2 million in tax credits through the state's jobs program after meeting job-creation goals, and $3.8 million in tax exemptions over 12 years.
Project Announcements
Canada-Based Dainty Foods Plans Batavia Township, Ohio, Manufacturing Operations
03/08/2026
AeroVironment Expands Albuquerque, New Mexico, Manufacturing Operations
03/08/2026
First Quality Home Care Products Plans Archbold, Ohio, Production Facility
03/08/2026
PPG Expands Delaware, Ohio, Manufacturing Operations
03/08/2026
J.M. Smucker Company Expands Topeka, Kansas, Operations
03/05/2026
Novartis Gene Therapies Plans Denton, Texas, Operations
03/04/2026
Most Read
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Speed Built In—The Real Differentiator for 2026 Site Selection Projects
Q1 2026
-
What Companies Need from Modern Manufacturing Sites
Q1 2026
-
Preparing for the Next USMCA Shake-Up
Q4 2025
-
The New Industrial Revolution in Biotech
Q4 2025
-
Capitalizing on the OBBBA Before the 2026 Cliff
Q1 2026
-
Strategic Industries at the Crossroads: Defense, Aerospace, and Maritime Enter 2026
Q1 2026